2025-06-13-花旗集团-Ascletis_Pharma（1672）_Ascletis_Pharma（1672.HK）_领先的肥胖研发公司_口服GLP_-_1具有高授权潜力；首次给予买入_高风险评级_目标价20港元_36页_1mb

Analyst Take:
Citi initiates Buy/High-Risk coverage on Ascletis Pharma (1672.HK) with a target price HK$20 (140% upside). The company is a leader in obesity R&D, and ASC30 demonstrated strong Phase 1b weight loss efficacy (6.5% at Week 4) and good safety/tolerability, with high out-licensing potential to big pharma (e.g., Pfizer, Roche). Upcoming Phase 2a data and potential collaborations are key catalysts.

Product Pipeline:

• ASC30: Oral GLP-1 RA, Phase 2a study planned for H2 2025. Potential market size of US$3.8bn by 2037 in the US/EU.
• ASC30 SQ: Once-monthly subcutaneous GLP-1 injection, Phase 2a to launch in 3Q 2025.
• ASC47: Adipose-targeted THRβ agonist, Phase 1b study showed muscle-preservation in weight loss.
• Denifanstat: Acne treatment showing superior efficacy in Phase 3 study, with first commercial potential in China.
• ASC50: IL-17 inhibitor for psoriasis in Phase 1.

Market Potential:

• ASC30: Oral obesity drug with orfor-scaffold, competitive safety profile vs peers. Market opportunity estimated at US$3.8bn peak sales (2037E).
• ASC30 SQ: Targeting higher dosing intervals for weight management.
• ASC47: Option for muscle-preservation in weight loss.
• Denifanstat: Acne market to reach Rmb793mn peak sales (2037E).

Financials:

• Revenue: Highly diluted, shifted from RMB54mn in 2022 to projected HK$101mn in 2025, but substantial losses persist.
• DCF Valuation: Based on WACC 10.4% and perpetual growth rate 2.0%, target price HK$20 reflects revenue and margin growth out to 2037E.
• Capital Structure: Significant cash reserves (HK$924bn market cap), high debt risk, ongoing fundraising efforts.

Risks:

• Lack of Profitability: Company remains loss-making with long-term revenue reliance.
• Clinical Failure: ASC30/ASC47 may fail clinical trials or face delays.
• Sales Execution: Uncertainty in commercialization, competition, pricing.
• Geopolitical: Risk to licensing due to deals timing/conditions.

Key Catalysts:

1. ASC30 Phase 2a data (H2 2025).
2. Potential big pharma collaboration for ASC30/ASC47.
3. Denifanstat NDA approval in China (expected H2 2025).
4. ASC30 Phase 1b data presentation (Jun/Jul 2025).

Investment Thesis:

• Buy/High-Risk driven by upside from clinical data, partnership potential, and China acne market entry.
• Risk factors emphasize uncertainty in commercial track record, political / market timing, and clinical progression.